Glenmark Pharms Ltd Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLENMARK PHARMS LTD
GLENMARK PHARMS LTD has one hundred and forty-five approved drugs.
There are eight tentative approvals on GLENMARK PHARMS LTD drugs.
Summary for Glenmark Pharms Ltd
| US Patents: | 0 |
| Tradenames: | 119 |
| Ingredients: | 110 |
| NDAs: | 145 |
Drugs and US Patents for Glenmark Pharms Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharms Ltd | AMPHETAMINE SULFATE | amphetamine sulfate | TABLET;ORAL | 212186-002 | Jan 27, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Glenmark Pharms Ltd | ADAPALENE AND BENZOYL PEROXIDE | adapalene; benzoyl peroxide | GEL;TOPICAL | 208108-001 | Nov 8, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glenmark Pharms Ltd | TACROLIMUS | tacrolimus | OINTMENT;TOPICAL | 210393-002 | Aug 16, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GLENMARK PHARMS LTD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
